Predicting potential pharma side effects

A computer program that can predict whether or not a given pharmaceutical will have worrying side effects has been developed by researchers in the USA. Jamiul Jahid and Jianhua Ruan of the Department of Computer Science, at the University of Texas at San Antonio, have developed the "in silico" testing system for drugs in the early stage of drug development.

Similar programs have been attempted before with varying degrees of success but the new software takes an "ensemble approach" to assessing the chemical structure of a drug molecule. It can thus determine whether key sub-structures are present in the molecule that are known to give rise to side effects in other drugs.

The team has tested the new program on almost 900 drugs against a database of 1385 side effects and demonstrated that it outstrips earlier software. The software has now been used to "test" compounds in the DrugBank database. The system could be used to alert the regulatory authorities and healthcare workers as to what side effects might occur when a new drug enters late-stage clinical trials and is ultimately brought to market. After using the software to screen 2883 small molecule uncharacterized drugs, the team was able to predict a large variety of side-effects, notably ones that were missed by other methods. "Based on drug side-effect information from different sources, we verify that the prediction by our approach is indeed correct," the team reports in the journal.

The team points out that more than 2 million people are affected by adverse reactions to their medication each year in the USA alone and of those around 100,000 die from problems associated with the side effects. Of course, many of those people are seriously ill and there are many factors that mean the side effects may not necessarily be entirely to blame for the deaths. Nevertheless, software that can flag potential problems through computer screening in this way could reduce that number.

In addition to predicting side effects the identification of substructures that are associated with particular side effects could be used to help medicinal chemists understand the underlying mechanism by which that side effect arises and also then design out that character from their drug molecules in future, reducing the number of drugs that go through the R&D pipeline and then fail at in clinical trials because side effects appear.

Jahid, M.J. and Ruan, J. (2016) 'Structure-based prediction of drug side effects using a novel classification algorithm', Int. J. Computational Biology and Drug Design, Vol. 9, Nos. 1/2, pp.87-101.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...